Mylanta Recall Lawsuit Attorney


Mylanta Recall Lawsuit AttorneyJohnson and Johnson has recalled Mylanta its brand name over the counter product containing the drug Simethicone.

This Mylanta recall only applies unsold Mylanta and does not pose any danger to the general public.


Because of this, Do I Have A Lawsuit will not be accepting any Mylanta recall lawsuits at this time.

 Looking for hip replacement recall information?

Read More Here Depuy Hip Replacement Recall Implant Lawsuit

 


The reason for this recall is due to incorrect label information on Mylanta ingredient labels that failed to list the less then 1% by volume of alcohol used in Mylanta. This is an insignificant amount and does not pose any risk to the general public.


If you have purchased Mylanta and still have unused portions, you may continue to the remaining product as this recall will not result in any formula changes.
This Mylanta recall applies to retail , warehouse and other related commercial affiliates , partners and distributors of Mylanta.


Fast Facts:


Mylanta has previously been suspected in pregnancy complications


 In consultation with the U.S. Food and Drug Administration (FDA), Johnson & Johnson-Merck Consumer Pharmaceuticals, Co. (JJMCP) is recalling, from the wholesale and retail level, twelve MYLANTA® liquid products and one AlternaGEL® liquid product. JJMCP is conducting the recall in order to update the labeling for these products. The specific products involved, listed below, are being recalled in the United States and Puerto Rico.

JJMCP initiated the recall after an internal review revealed that information about the presence of alcohol from flavoring agents was not noted on the packaging. Certain flavoring agents contribute small (< 1%) amounts of alcohol. It is unlikely that use of these products will cause either alcohol absorption or alcohol sensitivity related adverse events.

This is a wholesale and retail level recall and is not being undertaken on the basis of adverse events. No action is required by consumers or healthcare providers and consumers can continue to use the product.

Consumers with questions should call our Consumer Care Center at 1-800-469-5268 (available Monday-Friday from 8 a.m. – 8 p.m. ET and Saturday – Sunday, 9 a.m. – 5 p.m. Eastern Time.)

The NDC codes and lot numbers for the recalled products can be found in the below list and on the bottle.

Known Mylanta Side Effects Not related to the Mylanta recall or any know Mylanta Lawsuit

Product

NDC Number

Lot Number

UPC

MYLANTA® REGULAR STRENGTH ORIGINAL 12 FL OZ

16837-162-12

AAF075, ABF005, ABF033

ABF068, ACF008, ACF054

ADF063, AEF024, AHF004

AHF016, AHF051, AJF026

ALF030, AMF016, AMF046

AMF047, APF064, APF074

ASF041, BAF028, BAF045

BAF049, BBF008, BCF051

BDF026, BDF045, BEF029

BEF043, BFF001, BFF020

BHF029, BHF031, BHF032

BJF017, BJF045, BJF046

BJF047, BLF025, BMF004

BMF023, SSF064, SSF078

716837610120

MYLANTA® ORIGINAL 5 FL OZ

16837-162-55

AAF071, AAF072, ADF048

ADF049, AFF016, AFF032

AJF038, AJF039, ASF056

BCF038, BDF046, BEF052

BFF003, BMF003, SSF053

716837610557

MYLANTA® REGULAR STRENGTH MINT 12 FL OZ

16837-138-12

ADF026, BCF037,

BHF028, SSF006

716837629122

MYLANTA® MAXIMUM STRENGTH CHERRY 12 FL OZ

16837-136-12

AAF022, ABF004, ABF067

ACF016, ADF011, ADF090

AEF051, AFF038, AHF003

AJF010, ALF050, APF028

BAF023, BCF010, BCF071

BCF086, BDF056, BEF054

BFF019, BFF034, BFF035

BFF042, BHF003, BJF005

BJF030, BMF005, BMF024

SPF066, SSF017, SSF051

SSF073

716837622123

MYLANTA® MAXIMUM STRENGTH MINT 12 FL OZ

16837-137-12

AAF091, ABF081, ACF039

ADF062, AEF030, AFF031

AHF015, ALF027, AMF033

APF063, BAF046, BCF035

BDF030, BEF028, BEF056

BFF018, BHF004, BJF018

BJF040, BJF041, BLF016

SPF067, SSF016

716837624127

MYLANTA® MAXIMUM STRENGTH ORIGINAL 12 FL OZ

16837-163-12

AAF073, AAF092, ACF007

ACF038, ACF059, ADF050

AEF025, AEF055, AEF060

AHF005, AHF044, AJF007

ALF049, APF076, ASF039

BAF009, BBF003, BCF036

BCF085, BDF034, BDF057

BEF031, BFF016, BHF011

BHF012, BHF027, BHF039

BJF011, BJF031, BLF001

BLF017, BMF018, BMF025

SSF014, SSF062, SSF075

716837652120

MYLANTA® MAXIMUM STRENGTH ORIGINAL 24 FL OZ

16837-163-24

AAF018, AAF023, ABF034

ABF066, ACF021, ACF027

ADF024, AHF035, AHF037

AJF025, ALF028, AMF039

ASF054, BAF014, BBF029

BCF084, BEF011, BEF023

BFF017, BHF006, BJF037

716837652243

MYLANTA® ULTIMATE STRENGTH MINT 12 FL OZ

16837-643-12

AJF008, ASF017

BDF017, BDF017A

716837643128

MYLANTA® ULTIMATE STRENGTH CHERRY 12 FL OZ

16837-644-12

ABF078, ADF013, ADF093

AFF015, AHF043, AJF006

AJF006A, ALF004, AMF026

APF031, ASF055, BBF014

BBF014A, BDF001, BDF055

BEF030, BHF024, BJF006

BJF019, BLF002, SPF024

716837644125

MYLANTA® SUPREME TASTING WITH CALCIUM CHERRY 12 FL OZ

16837-825-12

ACF040, AEF029, AHF045

ALF051, ASF040, BBF015

BEF026, BHF001, BJF032

SPF068

716837825128

MYLANTA® SUPREME TASTING WITH CALCIUM CHERRY 24 FL OZ

16837-825-24

AAF090, ADF023, AHF042

AMF040, BCF083, BHF038

716837825241

MYLANTA® MAXIMUM STRENGTH ORIGINAL 12 FL OZ

16837-163-12

0089N11, 0089N11A, 0089N11B

0369N11, 0369N21, 0559N28

0689N12, 0689N22, 1069N21A

1079N11, 1209N22A, 1219N12

1219N22, 1569N12, 1569N12A

1569N22, 2229N11, 2229N21

3068N12, 3588N21

716837652151

ALTERNAGEL® 12 FL OZ

16837-860-12

ADF012, ASF057, BLF006

716837860129

 

 

 

 

 

 

Mylanta Side Effects

Mylanta Side Effects - for the Consumer
Mylanta Gas Relief Maximum Strength
All medicines may cause side effects, but many people have no, or minor, side effects. When used in small doses, no COMMON side effects have been reported with Mylanta Gas Relief Maximum Strength. Seek medical attention right away if any of these SEVERE side effects occur when using Mylanta Gas Relief Maximum Strength:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).


Mylanta
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Mylanta:

Constipation; diarrhea; stomach upset.

Seek medical attention right away if any of these SEVERE side effects occur when using Mylanta:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); loss of appetite; muscle weakness; nausea; slow reflexes; vomiting.


Mylanta Ultra Chewable Tablets
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Mylanta Ultra Chewable Tablets:

Constipation; diarrhea; stomach upset.

Seek medical attention right away if any of these SEVERE side effects occur when using Mylanta Ultra Chewable Tablets:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); loss of appetite; muscle weakness; nausea; slow reflexes; vomiting.


Mylanta Suspension
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Mylanta Suspension:

Constipation; diarrhea.

Seek medical attention right away if any of these SEVERE side effects occur when using Mylanta Suspension:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); loss of appetite; muscle weakness; nausea; slow reflexes; vomiting.


Mylanta Supreme Suspension
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Mylanta Supreme Suspension:

Constipation; diarrhea; stomach upset.

Seek medical attention right away if any of these SEVERE side effects occur when using Mylanta Supreme Suspension:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); loss of appetite; muscle weakness; nausea; slow reflexes; vomiting.


Side Effects

Gastrointestinal side effects have been reported the most frequently. These have included constipation (secondary to aluminum hydroxide therapy) and diarrhea (secondary to magnesium hydroxide therapy). These agents are combined so lower doses may be used and the constipating and diarrheal effects may be balanced out. However, diarrhea appears to be the dominating effect, regardless of the ratio. Rarely, gastrointestinal obstruction has occurred with the use of aluminum hydroxide.


Sources of aluminum in patients with renal failure have included water used for dialysate solutions, in addition to aluminum hydroxide. Adverse effects of aluminum accumulation in these patients has led to monitoring of water source aluminum content by dialysis units and periodic measurements of serum aluminum in patients undergoing chronic dialysis.

High aluminum concentrations in patients are generally also associated with high daily dosage. One study suggested that increased aluminum concentrations in uremic patients was most significant with daily doses greater than 3 grams of aluminum hydroxide. Age of the patient has also been directly correlated with aluminum concentrations, with younger age groups perhaps demonstrating higher concentrations.

Concurrent administration of aluminum hydroxide with citrate containing products has been associated with unusually high serum concentrations of aluminum and, especially in cases of renal failure, severe toxicity. It was speculated that citrate increases aluminum's solubility and absorption.

Aluminum concentrations during aluminum hydroxide therapy have also been correlated with body iron stores. One study demonstrated a negative correlation between serum aluminum concentrations and serum ferritin levels. It was postulated that high serum ferritin and high transferritin saturation might hamper gut absorption of aluminum.

During long-term use, aluminum has been shown to deposit in bone, joints, and the brain of patients who accumulate aluminum.

Signs and symptoms of hypermagnesemia may include hypotension, nausea, vomiting, EKG changes, respiratory depression, altered mental status, and coma.

Although the majority of aluminum ingested is eliminated by the gastrointestinal tract, absorption of aluminum and increases in serum concentrations have been demonstrated. Accumulation of aluminum and resulting toxicity is confined to patients with renal dysfunction and impaired elimination of aluminum.

Magnesium may be systemically absorbed following administration of magnesium hydroxide. In patients with normal renal function, increased magnesium elimination in the urine occurs and no significant changes in serum magnesium levels would be expected. However, magnesium may accumulate in patients with renal insufficiency.


Aluminum hydroxide complexes with phosphate in the gut to form insoluble aluminum phosphate, thus inhibiting the absorption of dietary phosphate. Aluminum hydroxide is commonly used in patients with renal dysfunction to regulate the accumulation of phosphate due to decreased elimination.

Hypophosphatemia is thought to stimulate the conversion of calcifediol (25-hydroxy vitamin D3) to calcitriol (1,25-dihydroxy vitamin D3), a potent stimulator of calcium and phosphorus intestinal absorption and osteoclastic resorption. Hypercalciuria is generally associated with hypophosphatemia.

Metabolic side effects have included hypophosphatemia with the use of aluminum hydroxide. In patients on long-term aluminum hydroxide therapy, especially in association with poor diets, hypophosphatemia may result in muscle weakness, rhabdomyolysis, hemolysis, and encephalopathy.


Musculoskeletal side effects have included osteomalacia, due to aluminum hydroxide, which may occur by two different mechanisms. Osteomalacia may occur due to hypophosphatemia or due to aluminum accumulation in bone. Osteomalacia due to hypophosphatemia is often accompanied by malaise, bone pain, muscular weakness, and bone fractures. Osteomalacia due to aluminum deposition may present in a similar fashion and occurs predominantly in patients with chronic renal failure. Aluminum deposits are seen on bone biopsy.

Aluminum hydroxide associated hypophosphatemia, if severe and chronic, results in decreased bone mineralization and potentially osteomalacia. Hypophosphatemia is also thought to stimulate the conversion of calcifediol (25-hydroxy vitamin D3) to calcitriol (1,25-dihydroxy vitamin D3), a potent stimulator of osteoclastic resorption, contributing to osteomalacia. These patients generally require phosphorus replacement therapy. Symptoms of osteomalacia may take several weeks to resolve.

Osteomalacia due to aluminum deposition in bone is generally only seen in patients with chronic renal failure. Bone formation slows in response to aluminum bone deposits. Aluminum may also deposit in joint tissue, resulting in arthropathy and hydrarthrosis.


Encephalopathy associated with aluminum accumulation is generally characterized by speech disorders, dysarthria, dyspraxia, dysphasia, tremor, myoclonus, seizures, coma, and death. EEG of patients with aluminum encephalopathy has shown paroxysmal slowing, and diffuse rhythmical bursts of delta activity.

The interval between commencement of aluminum hydroxide therapy and development of encephalopathy in eight reported cases ranged from three weeks to three months. In two of these patients, aluminum serum concentrations ranged from 871 to 2267 mcg/L. These patients were on concomitant sodium citrate therapy. Most chronic dialysis patients develop aluminum encephalopathy slowly over several years.

Nervous system side effects have included encephalopathy which has occasionally been reported in patients with renal failure on long-term therapy with aluminum hydroxide. When available, basal and/or deferoxamine stimulated aluminum serum levels reveal high concentrations.


Renal side effects have rarely included formation of renal calculi, most probably due to hypercalciuria, with the use of aluminum hydroxide.


Antacids may interfere with drug therapies because of their effect on gastric pH, adsorption or binding to drugs, and changes in urinary pH.

 

Discuss this article in the forums (0 replies).